Preparation and use of compounds as aspartyl protease inhibitors
AssigneeSchering Corporation
InventorsBrian McKittrick, Zhaoning Zhu, Andrew Stamford, Elizabeth M. Smith
Life of this patent
Estimating the term…
Loading patent…
AssigneeSchering Corporation
InventorsBrian McKittrick, Zhaoning Zhu, Andrew Stamford, Elizabeth M. Smith
Estimating the term…
Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein A is a bond, —C(O)—, or —C(R3′)(R4′)—; X is —N(R1)— or —C(R6)(R7)—; Y is —S(O)2—, —C(═O)—, —PO(OR9) or —C(R6′R7′)—; is a single or double bond and R, R1, R2, R3, R4, R3′, R4′, R5, R6, R6′, R7 and R7′ are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic antagonist.
A compound having the structural Formula IA:
A compound having the structural formula IA:
Dependencies are inferred from the claim text.